<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1265">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04718480</url>
  </required_header>
  <id_info>
    <org_study_id>SD-COVID19-01</org_study_id>
    <secondary_id>2020-002299-11</secondary_id>
    <nct_id>NCT04718480</nct_id>
  </id_info>
  <brief_title>Fluvoxamine Administration in Moderate SARS-CoV-2 (COVID-19) Infected Patients</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Adaptive-design Study to Assess the Safety and Efficacy of Daily 200 mg Fluvoxamine as add-on Therapy to Standard of Care in Moderate Severity COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SigmaDrugs Research Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SigmaDrugs Research Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, adaptive two-stage design, human&#xD;
      phase 2 study, with add-on treatment arrangement of fluvoxamine or placebo on top of standard&#xD;
      of care (base therapy: the actual proposed therapy of moderate SARS-CoV-2 infected patients&#xD;
      according to &quot;Hungarian Coronavirus Handbook&quot;, including antiviral and immunmodulant therapy&#xD;
      and reconvalescent plasma therapy in serious cases as indicated by the investigator).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 27, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, placebo-controlled, adaptive design add-on treatment study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blind, placebo-controlled,</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time to clinical recovery after treatment</measure>
    <time_frame>74 days</time_frame>
    <description>days from randomization (Day 1) to ANY THREE items of the following four:&#xD;
resolution from fever (oral or tympanic temperature ≤ 37.5 °C, axillary ≤ 37.0 °C for at least 48 hours without antipyretics)&#xD;
return of respiratory rate to normal (≤ 20 / min)&#xD;
normalization of SpO2 ( ≥95% on room air )&#xD;
cough remission (any reduction in cough-burden Visual Analogue Scale, compared to Day 1 baseline)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 x 100 mg placebo daily po. (with careful dose escalation and tapered dose reduction). Overall treatment period is 74 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluvoxamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 x 100 mg fluvoxamine daily po. (with careful dose escalation and tapered dose reduction). Overall treatment period is 74 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>po placebo tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluvoxamine</intervention_name>
    <description>po fluvoxamine tablets</description>
    <arm_group_label>Fluvoxamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females 18-70 years of age at screening&#xD;
&#xD;
          -  Hospitalized patients with confirmed SARS-CoV-2 by PCR or known contact of confirmed&#xD;
             case with syndrome consistent with coronavirus disease (COVID-19) with PCR pending&#xD;
             (positive PCR result should be available prior to randomisation).&#xD;
&#xD;
          -  Moderate cases (each of the followings met): showing dyspnoea but not manifest&#xD;
             respiratory distress, respiratory rate 22-29 / min; oxygen saturation at rest &gt; 93%;&#xD;
             with or without the need for oxygen supplementation; pneumonia on medical imaging with&#xD;
             pulmonary infiltrates occupying ≤ 50% of the lung-fields&#xD;
&#xD;
          -  Subjects who are able to communicate with the Investigator and research staff, who&#xD;
             understand the study, are able to comply with all study procedures, and willing to&#xD;
             provide written informed consent prior to the screening examinations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Mild COVID-19 at randomisation (each of the followings met): no dyspnoea, respiratory&#xD;
             rate &lt; 22 / min, no need for oxygen supplementation, no pneumonia on medical imaging&#xD;
&#xD;
               -  Severe COVID-19 at randomisation: respiratory distress - respiratory rate ≥&#xD;
                  30/min, oxygen saturation at rest ≤ 93%, pulmonary infiltrates occupy &gt; 50% of&#xD;
                  the lung-fields&#xD;
&#xD;
               -  Critical COVID-19 at randomisation: acute respiratory distress, requiring&#xD;
                  mechanical ventilation, radiomorphology of ARDS, shock, including septic shock,&#xD;
                  other organ dysfunction necessitating ICU admission&#xD;
&#xD;
               -  High-risk patient for progression of COVID-19, as defined by having a calculated&#xD;
                  pneumonia PORT-score of &gt; 90&#xD;
&#xD;
               -  Concomitant or previous administration of any experimental, non-established&#xD;
                  COVID-19 therapy, either in off-label indication (of a registered medicinal&#xD;
                  product) or as a non-registered drug candidate in a clinical trial setting or&#xD;
                  compassionate use program (or equivalents thereof), EXCEPT therapies recommended&#xD;
                  by the &quot;Magyar Koronavírus Kézikönyv&quot; (Hungarian Coronavirus Manual), and as&#xD;
                  such, are considered as standard-of-care. Concomitant use of LMWHs can be&#xD;
                  considered as emerging standard-of-care, and therefore their application is not&#xD;
                  prohibited.&#xD;
&#xD;
               -  Standard of care treatment planned with chloroquine or hydroxychloroquine.&#xD;
&#xD;
               -  Any clinically significant abnormality identified during pre-study full physical&#xD;
                  examination, vital signs, laboratory tests and ECG which is deemed by the&#xD;
                  Investigator to be incompatible / inappropriate for study participation.&#xD;
&#xD;
               -  Known hepatitis B, C, or HIV infection.&#xD;
&#xD;
               -  A current or recent history of drug or substance abuse, including alcohol (&gt; 14&#xD;
                  units per week), within 3 months prior to screening (one unit of alcohol equals ½&#xD;
                  pint [285 mL] of beer or lager, one glass [125 mL] of wine, or one shot [25 mL]&#xD;
                  of spirits)&#xD;
&#xD;
               -  Patients who regularly consume more than 4 cups daily of beverage containing&#xD;
                  caffeine&#xD;
&#xD;
               -  Current strong smoker as defined by smoking over 10 cigarettes a day, or its&#xD;
                  equivalent&#xD;
&#xD;
               -  Positive pregnancy test result for women with childbearing potential at screening&#xD;
&#xD;
               -  Women who are pregnant or nursing, or who are planning to get pregnant within 3&#xD;
                  months after the last dose of study drug&#xD;
&#xD;
               -  A history of allergy, intolerance or sensitivity to fluvoxamine or any component&#xD;
                  of the study drug formulation&#xD;
&#xD;
               -  Closed-angle glaucoma&#xD;
&#xD;
               -  Patients who are assessed as at risk for suicidal intent during screening by&#xD;
                  psychiatric evaluation (including C-SSRS questionnaire). A score of 15 or higher&#xD;
                  on the PHQ-9 depression scale at screening.&#xD;
&#xD;
               -  Have undergone surgery or have donated blood within 12 weeks prior to the start&#xD;
                  of the study&#xD;
&#xD;
               -  A history of bleeding diathesis or other bleeding disorders&#xD;
&#xD;
               -  Participated in any clinical trial involving an investigational drug or&#xD;
                  investigational device within 1 month preceding study entry, or within 5 terminal&#xD;
                  half-life of the investigational drug of this previous study&#xD;
&#xD;
               -  A history of or present malignancy, with the exception of resected basal cell&#xD;
                  carcinoma or squamous cell carcinoma of the skin, or resected cervical&#xD;
                  intraepithelial neoplasia.&#xD;
&#xD;
        Prohibited concomitant medications:&#xD;
&#xD;
          -  Co-administration of fluvoxamine with monoamine oxidase inhibitors (MAOI), including&#xD;
             methylene blue (intravenous dye) and linezolid (an antibiotic which is a reversible&#xD;
             non-selective MAOI)&#xD;
&#xD;
          -  Co-administration of thioridazine, mesoridazine, pimozide, terfenadine, astemizole, or&#xD;
             cisapride with fluvoxamine; each of these drugs alone produces prolongation of the QTc&#xD;
             interval, which is associated with serious ventricular arrhythmias, such as torsade de&#xD;
             pointes-type arrhythmias and sudden death&#xD;
&#xD;
          -  Co-administration of tizanidine and fluvoxamine&#xD;
&#xD;
          -  Co-administration of fluvoxamine with ramelteon&#xD;
&#xD;
          -  Co-administration of fluvoxamine with chloroquine or hydroxychloroquine&#xD;
&#xD;
          -  Co-administration of morphine, or other opioids.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrea Fekete, PhD</last_name>
    <phone>0036309472333</phone>
    <email>andrea.fekete@sigmadrugs.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dóra FAZEKAS, Dr</last_name>
    <phone>+36707010091</phone>
    <email>dora.fazekas@cortexps.hu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dél-pesti Centrumkórház</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>János Szlávik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem Pulmonológiai Klinika</name>
      <address>
        <city>Budapest</city>
        <zip>H-1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Veronika Müller, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Országos Korányi Pulmonológiai Intézet</name>
      <address>
        <city>Budapest</city>
        <zip>H-1121</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>János Varga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Krisztina Tóth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Kenézy Gyula Kórház Infektológia</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>István Várkonyi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 18, 2021</study_first_submitted>
  <study_first_submitted_qc>January 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>January 20, 2021</last_update_submitted>
  <last_update_submitted_qc>January 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>moderate COVID-19; fluvoxamine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluvoxamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Study results will be published at the end of the study.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

